Latest

Optum
Pharmalot

Ohio seeks $16m from UnitedHealth’s PBM for overcharging on drugs

By Ed Silverman

Pharmalot

Pharmalittle: Insulin makers must face price-gouging claims; Allergan agrees to independent chair during next transition

By Ed Silverman

Fatty Liver
Biotech

With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

By Adam Feuerstein

The Readout

CRISPRing vaccines, alleging price-fixing, & placing blame for insulin pricing

By Damian Garde

Morning Rounds

New details in generic price-fixing lawsuit, 9/11 health fund, & a flu update

By Megan Thielking

MilliporeSigma
Biotech

Stealth player is poised to win a CRISPR patent that could speed the development of therapies

By Sharon Begley

Open vault
First Opinion

Move clinical trial data sharing from an option to an imperative

By Rebecca Li

Nutrition labels - choices
First Opinion

Do food and menu nutrition labels influence consumer or industry behavior?

By Dariush Mozaffarian and Siyi Shangguan

Human B Lymphocyte
In the Lab

Vaccines don’t work against some viruses. CRISPR might one day fix that

By Sharon Begley

Colorful selection of pills
Pharmalot

Here’s how prosecutors say generic drug makers schemed to fix prices

By Ed Silverman

Insulin NOVO NORDISK
Politics

‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around

By Nicholas Florko

Hep C San Fran
Pharmalot

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

By Ed Silverman

Jim Wilson
Biotech

Once a ‘refugee,’ a gene therapy pioneer finds a renewed calling as the field advances

By Damian Garde

Health

In space, NASA heard astronaut’s immune system scream

By Associated Press

electronic med records
Health

‘Dancing in the streets’: Health tech leaders emboldened by U.S. plan to free up patient data

By Casey Ross

human T cells in culture
Politics

Medicare would provide national coverage for CAR-T cancer therapies under new proposal

By Ike Swetlitz

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Company buys drug and raises price 70 percent; Oklahoma opioid trial is the one to watch

By Ed Silverman

The READOUT
The Readout

Drug pricing realpolitik & a (premature) look at IPOs

By Damian Garde

Flu Shot Clinic
Morning Rounds

Washington weighs vaccine rules & a flu shot update

By Megan Thielking

U.S. Rep. Rosa DeLauro
Politics

NAFTA 2.0’s impact on drug prices is more complicated than some Democrats are implying

By Ike Swetlitz

Medical costs photo illustration
First Opinion

Seema Verma: Americans have the right to know their health care and hospital costs

By Seema Verma

Cambridge flood
Business

Hurricanes, droughts, and wildfires: How biopharma is girding for climate change

By Kate Sheridan

The Readout LOUD

LISTEN: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Michael Babich
Business

Former Insys CEO said he was made the ‘fall guy’ for opioid maker Insys

By Maria Cramer — Boston Globe

Pharmalot

Italy proposes the WHO set international standards for drug-pricing transparency

By Ed Silverman

2018-19 flu vaccine
Health

Flu shots this winter providing moderate levels of protection, CDC data show

By Helen Branswell

Racial bias Pain Management
Pharmalot

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

By Ed Silverman

FDA campus
Politics

Draft federal spending deal includes largest boost for FDA in five years

By Ike Swetlitz and Nicholas Florko

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy